Axsome Therapeutics Provides Preliminary Fourth Quarter and

1 day ago · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 million and $385.2 million for the fourth quarter and full …

$118
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And

2 weeks from now

1 day ago · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 million and $385.2 million for the fourth quarter and full …

globenewswire.com

$118
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

1 day ago · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 million and $385.2 million for the fourth quarter and full …

yahoo.com

$71
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

Jan 4, 2024 · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of …

yahoo.com

$22
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year

2 weeks from now

Feb 20, 2024 · Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ... were $22.5 million and $74.8 million for the fourth …

globenewswire.com

$71
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And

2 weeks from now

Jan 4, 2024 · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of …

globenewswire.com

7%
OFF

Axsome (AXSM) Stock Rises On Stellar Q4 Preliminary Results

2 weeks from now

Jan 5, 2024 · Shares of Axsome Therapeutics, Inc. AXSM were up 7.7% on Jan 4 after the company announced robust preliminary results for the fourth quarter and full-year 2023. …

nasdaq.com

$71
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

Jan 4, 2024 · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of …

businessinsider.com

$19
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Feb 27, 2023 · Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May …

yahoo.com

$25
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

2 days ago · Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 million, respectively. NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Axsome …

financialpost.com

$92
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

1 day ago · Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectivelySunosi preliminary 4Q and full year 2024 net product revenue of …

tradingview.com

$92
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively. Sunosi preliminary 4Q and full year 2024 net product revenue of $25

researchpool.com

$103
OFF

TG Therapeutics Provides Preliminary Fourth Quarter And Full Year …

2 weeks from now

17 hours ago · Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of …

businessinsider.com

$71
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

Jan 4, 2024 · Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of …

financialpost.com

FAQs about Axsome Therapeutics Provides Preliminary Fourth Quarter and Coupon?

What did Axsome Therapeutics announce in Q4 2023?

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and full year ended December 31, 2023. ...

How much revenue does Axsome expect in 2024?

Preliminary Fourth Quarter and Full Year 2024 Net Product Revenue (Unaudited) Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 million and $385.2 million for the fourth quarter and full year of 2024, respectively. ...

Who is Axsome Therapeutics?

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. ...

How many patients did Axsome have in 2023?

“Axsome completed its first full year as a commercial company in 2023 and, during that time, our medicines reached approximately 100,000 unique patients. Prescriptions for Auvelity and Sunosi totaled more than 236,000 and 139,000, respectively for the full year,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. ...

What is Axsome doing in 2024?

Axsome is advancing an industry-leading neuroscience portfolio encompassing five innovative late-stage product candidates for 10 serious conditions, which affect more than 150 million people in the U.S. alone. 2024 anticipated milestones for key pipeline programs are summarized below. ...

Was 2024 a good year for TG Therapeutics?

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “2024 was a great year for TG, and we are excited to share preliminary fourth quarter and year end U.S. BRIUMVI net product revenue which far exceeded our initial expectations. ...